Dependence, Cocaine
Conditions
Keywords
Diagnosis of dependence on cocaine according to DSM-IV-TR criteria
Brief summary
The purpose of this study is to assess the phenotypic candidates symptoms, in patients with crack/cocaine addiction, in terms of clinical comorbidities, dimensions of personality, and neuropsychological evaluations apt to be associated with genetic and genotypic characterisations, notably on the polymorphisms of the genes coding or regulating dopaminergic, norepinephrine and serotoninergic systems.
Detailed description
Genetic studies show an association between drug addiction and the dopaminergic system and its modulators. Nonetheless, results are contradictory, partially due to the heterogeneity of the phenotype addiction. Placed on the trafficking route of cocaine, and homogeneously populated, Martinique is of particular interest for the study of the vulnerability of the crack/cocaine addiction. In a precedent study, supported by a grant MILDT / INSERM 2000, on 155 men dependent to crack/cocaine and characterised with three clinical dimensions -sensation seeking, impulsivity and childhood ADHD- we found an association between each dimension and polymorphisms of DRD2 and DRD4 genes.
Interventions
GENETICCollect 10 ml of Saliva for DNA extraction
After signed written informed consent, all patients and controls have clinical and neuropsychological evaluations (DIGS, WURS, BROWN, BIS, SSS and IGT) for phenotypic diagnosis and collection of saliva for DNA extraction and genotyping diagnosis.
Sponsors
University Hospital Center of Martinique
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Diagnosis of cocaine abuse/dependence according to DSM-IV-TR criteria * Come from French West Indies (3 grandparents are African-Caribbean) * Sign a written informed consent
Exclusion criteria
* Minor * Men with no cocaine abuse/dependence according to DSM-IV-TR criteria For the control: Inclusion Criteria: * Platelets donor * No substance abuse/dependence according to DSM-IV-TR criteria * Come from French West Indies (3 grandparents are African-Caribbean) * Sign a written informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The specific measure that will be related to core objectives of the study is to constitute a sample collection from saliva. | The saliva will be collect at the end of the first visit |
Countries
France
Contacts
Primary ContactJérôme LACOSTE, MD
Backup ContactJocelyne CRASPAG, Master
Outcome results
None listed